Swiss (SMI) Clinical Research and Equipment Industry Analysis

UpdatedAug 10, 2025

DataAggregated Company Financials

Companies7

7D-4.8%
3M-3.3%
1Y-8.8%
YTDn/a

Over the last 7 days, the Clinical Research and Equipment industry has dropped 5.7%, driven by pullbacks from every company within the industry. Overall the industry is down 9.4% in 12 months. Looking forward, earnings are forecast to grow by 20% annually.

Industry Valuation and Performance

Has the Swiss Clinical Research and Equipment Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Sun, 10 Aug 2025	CHF 51.6b	CHF 10.7b	CHF 1.1b	33.4x	44.9x	4.8x
Tue, 08 Jul 2025	CHF 52.0b	CHF 10.1b	CHF 1.0b	32.7x	50x	5.2x
Thu, 05 Jun 2025	CHF 52.1b	CHF 10.1b	CHF 1.0b	30.8x	50.1x	5.2x
Sat, 03 May 2025	CHF 55.0b	CHF 10.1b	CHF 1.0b	31.5x	52.9x	5.5x
Mon, 31 Mar 2025	CHF 53.1b	CHF 10.1b	CHF 1.0b	33.1x	51.8x	5.3x
Wed, 26 Feb 2025	CHF 55.4b	CHF 10.1b	CHF 1.0b	32.5x	53.4x	5.5x
Fri, 24 Jan 2025	CHF 56.5b	CHF 10.2b	CHF 943.2m	35.9x	59.9x	5.5x
Sun, 22 Dec 2024	CHF 52.2b	CHF 10.2b	CHF 943.6m	35.2x	55.3x	5.1x
Tue, 19 Nov 2024	CHF 51.8b	CHF 10.2b	CHF 943.5m	40.9x	54.9x	5.1x
Thu, 17 Oct 2024	CHF 54.4b	CHF 10.2b	CHF 943.4m	41.3x	57.7x	5.3x
Sat, 14 Sep 2024	CHF 57.5b	CHF 10.2b	CHF 937.0m	44.5x	61.3x	5.6x
Mon, 12 Aug 2024	CHF 57.4b	CHF 10.2b	CHF 924.0m	45.2x	62.2x	5.6x
Wed, 10 Jul 2024	CHF 54.0b	CHF 10.3b	CHF 1.0b	46.6x	53.9x	5.3x
Fri, 07 Jun 2024	CHF 53.6b	CHF 10.3b	CHF 1.0b	43.9x	53.5x	5.2x
Sun, 05 May 2024	CHF 54.4b	CHF 10.3b	CHF 1.0b	43.4x	54.3x	5.3x
Tue, 02 Apr 2024	CHF 58.5b	CHF 10.3b	CHF 1.0b	47x	58.3x	5.7x
Thu, 29 Feb 2024	CHF 50.6b	CHF 10.2b	CHF 982.4m	46.9x	51.6x	5x
Sat, 27 Jan 2024	CHF 46.5b	CHF 10.2b	CHF 1.0b	42.3x	45.6x	4.6x
Mon, 25 Dec 2023	CHF 41.8b	CHF 9.8b	CHF 1.5b	32.4x	28x	4.3x
Wed, 22 Nov 2023	CHF 41.3b	CHF 9.8b	CHF 1.5b	29.5x	27.7x	4.2x
Fri, 20 Oct 2023	CHF 39.1b	CHF 9.8b	CHF 1.5b	27.2x	26.2x	4x
Sun, 17 Sep 2023	CHF 52.6b	CHF 9.8b	CHF 1.5b	35.4x	35.3x	5.4x
Tue, 15 Aug 2023	CHF 53.2b	CHF 9.8b	CHF 1.5b	35.5x	34.4x	5.4x
Thu, 13 Jul 2023	CHF 55.6b	CHF 9.7b	CHF 1.6b	37.2x	34x	5.7x
Sat, 10 Jun 2023	CHF 58.7b	CHF 9.7b	CHF 1.6b	37x	35.9x	6.1x
Mon, 08 May 2023	CHF 62.0b	CHF 9.7b	CHF 1.6b	41.3x	38x	6.4x
Wed, 05 Apr 2023	CHF 57.6b	CHF 9.7b	CHF 1.7b	41.7x	34.5x	5.9x
Fri, 03 Mar 2023	CHF 58.7b	CHF 9.6b	CHF 1.7b	34.3x	35.3x	6.1x
Sun, 29 Jan 2023	CHF 56.2b	CHF 9.6b	CHF 1.6b	32.4x	34.4x	5.9x
Tue, 27 Dec 2022	CHF 49.9b	CHF 9.2b	CHF 1.3b	37x	37.5x	5.4x
Thu, 24 Nov 2022	CHF 54.1b	CHF 9.2b	CHF 1.3b	40.5x	40.7x	5.9x
Sat, 22 Oct 2022	CHF 51.5b	CHF 9.2b	CHF 1.3b	40.2x	38.7x	5.6x
Mon, 19 Sep 2022	CHF 50.2b	CHF 9.2b	CHF 1.3b	39.5x	38.8x	5.5x
Wed, 17 Aug 2022	CHF 56.4b	CHF 8.9b	CHF 1.3b	35.1x	43x	6.3x

Price to Earnings Ratio

43x

Wed, 17 Aug 2022

Current Industry PE

Investors are relatively neutral on the Swiss Life Sciences Tools and Services industry at the moment, indicating that they anticipate long term growth rates to remain steady.

The industry is trading close to its 3-year average PE ratio of 44.8x.

The 3-year average PS ratio of 5.4x is higher than the industry's current PS ratio of 4.8x.

Past Earnings Growth

The earnings for companies in the Life Sciences Tools and Services industry have declined 4.3% per year over the last three years.
Meanwhile revenues for these companies have grown 6.2% per year.
This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.